Diagnostics & AI-assisted care in India, explained
By Abha Lohia · Startup Decoded
Diagnostics startups find out what is wrong by testing blood, images and genes, and AI-assisted care uses software to help read the results. They earn mostly per test, with software and devices on the side.
What is diagnostics and AI-assisted care?
Diagnostics is the testing step in healthcare. It covers blood and urine tests, scans such as X-rays and MRIs, heart readings such as an ECG, and genetic tests. Doctors use the results to decide on treatment, so it is the base of most medical decisions.
AI-assisted care means software helps with this work: reading an X-ray, flagging an unusual ECG, sorting a patient's records or predicting who needs attention first. The software supports the doctor rather than replacing the doctor.
In StopDown's data, the area includes Redcliffe Labs, an omnichannel diagnostic service provider, Healthians, which offers at-home testing, 4baseCare, which does genomics-driven cancer diagnostics, and Molbio Diagnostics, a Goa-based maker of diagnostic tests.
A few terms help when reading news about this area. A panel is a group of tests sold together, such as a thyroid panel. Turnaround time is how long a report takes to arrive. Pathology means tests on blood, urine and tissue, while radiology means scans such as X-rays and MRIs. Molecular diagnostics look for genetic material, and genomics studies a person's genes as a whole. When a funding story says a company is building an omnichannel diagnostics service, it usually means it sells through home collection, collection centres and partner clinics at once.
How did it grow in India?
India has a large number of small independent labs and a few big chains. Quality was uneven and patients often had to travel to collect results. Startups saw two chances: collecting samples from the home and giving results on a phone.
Home sample collection grew quickly, since a phlebotomist, a trained person who draws blood, could visit at a time that suits the patient. COVID-19 sped it up. Molecular testing, once rare, became widely known, and companies that make test kits gained experience in large-scale manufacture.
Today there are three strands. Consumer-facing labs sell tests and health packages. Technology firms sell tools to labs and clinics, such as ClinikPe, which launched a platform for small diagnostic labs. And device makers such as Sunfox, which raised a Series A for its Spandan ECG device, build tools that can be used outside big hospitals.
How do these businesses make money?
Most labs earn a fee for every test or package. The cost per test falls when a lab runs many samples on the same machines, so scale helps. A lab also earns more when it collects samples in one place and tests them in a central lab, called a hub-and-spoke model.
Home collection adds a convenience fee or a higher price. Some firms sell health check-up packages to employers or to insurers.
Device and software companies earn differently. A device company sells the machine and then sells the strips, kits or service that go with it. A software company charges labs or clinics a monthly fee. AI tools are often sold per scan or per hospital. Genomics firms may charge doctors or hospitals for each test and may add reports that help choose a treatment.
What rules apply?
Laboratories follow state and national rules on registration and quality. Many labs seek accreditation from NABL, the national accreditation body for testing laboratories, to show their results are reliable. Check which licences apply in your state.
Diagnostic kits and machines are medical devices. Under the Medical Devices Rules, 2017, administered by CDSCO, devices are placed in four risk classes, from A (low risk) to D (high risk), and need licences before manufacture, import or sale. Software that supports a diagnosis can also count as a medical device, depending on what it does.
Patient data is protected by the Digital Personal Data Protection Act, 2023, with its Rules notified in November 2025 and being phased in. Labs that join the Ayushman Bharat Digital Mission can share reports against a patient's ABHA number with consent. Tele-reporting and AI reading of scans should still involve a qualified doctor who signs off. This is general information, not legal advice.
Who are the customers?
Patients pay for most tests, either directly or through a doctor's referral. Many take annual health check-ups, and a growing group uses regular tests to track diabetes, thyroid or cholesterol. Home collection suits older people and busy families.
Hospitals and clinics buy devices, software and outsourced testing. Employers buy check-ups for staff. Insurers sometimes pay for tests as part of a policy or a wellness plan.
Doctors are quiet but powerful customers. A doctor who trusts a lab or an AI tool will send more patients to it, so earning that trust with accurate and timely reports is a business advantage.
How should you judge one, and what are the risks?
Start with quality: accreditation, how often results are repeated, and how the company handles complaints. A cheap test is poor value if the result cannot be trusted.
Then check the economics: the number of tests run per machine, how much of the work is done in the company's own lab, and what home collection costs per visit. A company with few orders in an area can lose money on every trip.
For AI tools, ask what evidence shows the software works on Indian patients, who is responsible for the final read, and how it fits the doctor's daily routine. A tool that adds work is rarely adopted.
The biggest risk is a wrong result. A mix-up of samples, a poor machine or a faulty AI model can lead to a wrong treatment, so quality control is the core of this business, not a side task.
Pricing is a second risk. Patients compare prices, and big chains and small labs discount, which squeezes margins. Home collection also costs money per visit, so companies need enough orders in each area.
Looking ahead, expect more AI reading of images and ECGs, more affordable devices for use in small clinics and villages, and more use of genetic tests in cancer care. Software for small independent labs is a visible trend. Investors in StopDown's health data include Elevation Capital, Bessemer Venture Partners and Blume Ventures.
The breakdown
Business models
| Model | How it makes money | Who uses it |
|---|---|---|
| Fee per test or package | Patient or employer pays for each test or health package | Diagnostic lab chains and home-testing services |
| Hub-and-spoke labs | Collect samples locally and test in one central lab | Large and mid-size lab networks |
| Device plus consumables | Sell the machine, then the kits and service | Test-kit and device makers |
| Software subscription | Labs or clinics pay a monthly fee | Lab software and AI scan-reading tools |
| Per-test genomic reports | Doctors or hospitals pay per genetic test | Genomics and cancer-diagnostics companies |
The numbers that matter
- Cost per test: falls as volume per machine rises.
- Average revenue per order: bigger when customers buy packages.
- Home-collection cost per visit and orders per route.
- Share of samples processed in the company's own lab.
- Rate of repeat tests or wrong results, which shows quality.
Rules and regulators
| Regulator or law | What it means |
|---|---|
| Medical Devices Rules, 2017, and CDSCO | Kits, machines and some software are devices that need risk-based licences. |
| NABL accreditation | A quality mark for labs; not always required but widely used to build trust. |
| State clinical establishment and registration rules | Labs must meet local registration and standards. |
| Digital Personal Data Protection Act, 2023 and Rules, 2025 | Protects patient data and requires breach reporting. |
Risks
- Wrong or delayed results from quality failures.
- Price competition that squeezes margins.
- High cost of home collection if orders are thin.
- Approval delays for new devices and AI tools.
- Doctors' trust in AI reading, which grows slowly.
Diagnostics & AI-assisted care: latest on StopDown
- ClinikPe launches platform for small diagnostic labs 8 October 2026
- Kinetic Age raises $250K from AJVC, Agrasar 6 October 2026
- Motilal Oswal fund sells 2% of Molbio 1 October 2026
- Netmeds revenue flat at ₹45 crore in FY26 30 September 2026
- Medoc Health raises seed funding for hospital automation 23 September 2026
- Theranautilus wins Top Innovator at ET Startup Awards 18 September 2026
- Practo reshuffles top leadership to drive global expansion 17 September 2026
- Vytalyou raises ₹8-10 crore growth funding 17 September 2026
Every Diagnostics & AI-assisted care story →
Most active investors here
- Inflexor Ventures (2 rounds)
- Abhishek Goyal (1 round)
- Accel India (1 round)
- Agrasar Ventures (1 round)
- Agrizy founders (1 round)
- AJVC (1 round)
- Ashish Gupta (1 round)
- Bayer Foundation (1 round)
Rounds StopDown covered in the last 12 months. Activity is not a measure of quality.
Questions people ask
What is a diagnostics startup?
A company that offers tests, scans or related software and devices to find out what is wrong with a patient. Examples include lab chains, home-testing services and genetic-testing firms.
How does home sample collection work?
A trained person visits the home, draws blood or takes another sample, and sends it to a lab. The report is then sent to the patient, usually on a phone.
Is AI used to read medical scans in India?
Yes, as a support tool. Hospitals and labs use it to flag unusual findings, but a qualified doctor is still expected to review the result.
Do diagnostic devices need approval in India?
Yes. Under the Medical Devices Rules, 2017, devices are grouped into four risk classes and need licences from CDSCO or state authorities, depending on class.
Which Diagnostics & AI-assisted care startups in India raised money recently?
Kinetic Age ($250K, Seed); Medoc Health (₹60 Lakhs, seed); Vytalyou (₹8-10 crore, growth); iKure Techsoft Private Limited ($1.8M, Pre-Series A); Orange Health ($30 million).
Who invests in Diagnostics & AI-assisted care startups in India?
Among the most active backers in StopDown's coverage over the last year: Inflexor Ventures, Abhishek Goyal, Accel India, Agrasar Ventures, Agrizy founders.
Which Diagnostics & AI-assisted care companies are in the news?
Recent stories on StopDown cover ClinikPe, Kinetic Age, Molbio Diagnostics, Netmeds, Medoc Health, Theranautilus, Practo, Vytalyou.
More in Healthcare & Life Sciences
Startup Decoded · Glossary · Sectors explained · Investor directory · FAQs